Advertisement
Screener

MACROGENICS, INC. (MGNX) Depreciation

2.8 / 5 stars · 68/120 Roast Me

MACROGENICS, INC. Depreciation

MACROGENICS, INC. (MGNX) reported Depreciation of $7.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.

Financial Statements › Cash Flow › Operating Activities

us-gaap:Depreciation · last filed 2026-03-09

  • MACROGENICS, INC. depreciation for the quarter ending 2020-12-31 was $2.93M, a 4.21% decline year-over-year.
  • MACROGENICS, INC. depreciation for the quarter ending 2020-09-30 was $2.96M, a 3.11% decline year-over-year.
  • MACROGENICS, INC. depreciation for the quarter ending 2019-12-31 was $3.06M.
  • MACROGENICS, INC. depreciation for the quarter ending 2019-09-30 was $3.06M.
  • MACROGENICS, INC. depreciation for fiscal 2025 was $7.20M, a 4.00% decline from fiscal 2024.
  • MACROGENICS, INC. depreciation for fiscal 2024 was $7.50M, a 21.88% decline from fiscal 2023.
  • MACROGENICS, INC. depreciation for fiscal 2023 was $9.60M, a 19.33% decline from fiscal 2022.
  • MACROGENICS, INC. depreciation for fiscal 2022 was $11.90M, a 5.31% increase from fiscal 2021.
Period endDepreciation 3 monthDepreciation 3 month as first filedDepreciation 6 monthDepreciation 9 monthDepreciation 9 month as first filedDepreciation 12 monthDepreciation 12 month as first filed
2025-12-31$7.20M
10-K · filed 2026-03-09
2024-12-31$7.50M
10-K · filed 2026-03-09
2023-12-31$9.60M
10-K · filed 2026-03-09
2022-12-31$11.90M
10-K · filed 2025-03-20
2021-12-31$11.30M
10-K · filed 2024-03-07
2020-12-31$2.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
$5.89M
derived: sum of 2 quarters · filed 2023-03-15
$12.00M
10-K · filed 2023-03-15
2020-09-30$2.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04
$9.07M
10-Q · filed 2020-11-04
2020-06-30$6.11M
10-Q · filed 2020-07-31
2019-12-31$3.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$6.12M
derived: sum of 2 quarters · filed 2022-02-24
$12.30M
10-K · filed 2022-02-24
2019-09-30$3.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04
$9.24M
10-Q · filed 2020-11-04
2019-06-30$6.18M
10-Q · filed 2020-07-31
2018-12-31$9.20M
10-K · filed 2021-02-25
2017-12-31$7.00M
10-K · filed 2020-02-25
2016-12-31$1.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$3.24M
derived: sum of 2 quarters · filed 2019-02-26
$5.03M
derived: sum of 3 quarters · filed 2019-02-26
$6.80M
10-K · filed 2019-02-26
2016-09-30$2.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02
$3.86M
derived: sum of 2 quarters · filed 2016-11-02
$5.63M
10-Q · filed 2016-11-02
$7.16M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$1.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
$3.56M
10-Q · filed 2016-08-03
$5.09M
derived: sum of 3 quarters · filed 2018-02-27
$5.58M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$1.77M
10-Q · filed 2016-05-04
$3.30M
derived: sum of 2 quarters · filed 2018-02-27
$3.79M
derived: sum of 3 quarters · filed 2018-02-27
$4.42M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31$1.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$2.02M
derived: sum of 2 quarters · filed 2018-02-27
$2.65M
derived: sum of 3 quarters · filed 2018-02-27
$3.20M
10-K · filed 2018-02-27
$2.86M
10-K · filed 2016-02-29
2015-09-30$489.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02
$1.13M
derived: sum of 2 quarters · filed 2016-11-02
$1.67M
10-Q · filed 2016-11-02
$2.15M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30$636.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
$1.18M
10-Q · filed 2016-08-03
$1.67M
derived: sum of 3 quarters · filed 2017-02-28
$2.15M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31$546.00K
10-Q · filed 2016-05-04
$1.03M
derived: sum of 2 quarters · filed 2017-02-28
$1.51M
derived: sum of 3 quarters · filed 2017-02-28
$1.95M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31$483.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
$965.00K
derived: sum of 2 quarters · filed 2017-02-28
$1.40M
derived: sum of 3 quarters · filed 2017-02-28
$1.80M
10-K · filed 2017-02-28
$1.82M
10-K · filed 2015-03-03
2014-09-30$482.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04
$919.00K
derived: sum of 2 quarters · filed 2015-11-04
$1.32M
10-Q · filed 2015-11-04
$1.68M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$437.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05
$835.00K
10-Q · filed 2015-08-05
$1.19M
derived: sum of 3 quarters · filed 2016-02-29
$1.51M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31$398.00K
10-Q · filed 2015-05-06
$398.22K
10-Q · filed 2014-05-06
$756.00K
derived: sum of 2 quarters · filed 2016-02-29
$1.07M
derived: sum of 3 quarters · filed 2016-02-29
$1.34M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$358.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$675.00K
derived: sum of 2 quarters · filed 2016-02-29
$940.82K
derived: sum of 3 quarters · filed 2016-02-29
$1.19M
10-K · filed 2016-02-29
$1.19M
10-K · filed 2014-03-20
2013-09-30$317.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12
$582.82K
derived: sum of 2 quarters · filed 2014-11-12
$835.00K
10-Q · filed 2014-11-12
$834.62K
10-Q · filed 2013-11-12
$1.07M
derived: sum of 4 quarters · filed 2015-03-03
2013-06-30$265.81K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05
$518.00K
10-Q · filed 2014-08-05
$755.50K
derived: sum of 3 quarters · filed 2015-03-03
2013-03-31$252.19K
10-Q · filed 2014-05-06
$489.69K
derived: sum of 2 quarters · filed 2015-03-03
2012-12-31$237.50K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03
$960.00K
10-K · filed 2015-03-03
$959.93K
10-K · filed 2014-03-20
2012-09-30$722.50K
10-Q · filed 2013-11-12
2011-12-31$1.15M
10-K · filed 2014-03-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35